The headline trial: No registration RCT in transplant recipients
Transplant patients were excluded from all GLP-1 RA registration trials. Observational case series and small open-label cohorts (Singh et al., Sweiss et al., 2022–2024) report cautious use in selected post-transplant patients with obesity.
Observational evidence only as of 2026
GLP-1 RA in post-transplant patients is increasingly used in obesity medicine practice but is off-label and requires multi-disciplinary coordination. Reported outcomes show meaningful weight loss with manageable side effects in selected patients, but transplant immunosuppression (especially tacrolimus, mycophenolate) creates drug-interaction and pharmacokinetic considerations.
Trial enrollment criteria
- Stable post-transplant status, at least 12 months post-transplant
- On stable immunosuppression with tacrolimus trough levels in target range
- Adequate graft function (eGFR appropriate for graft type)
- BMI greater than or equal to 30 with documented post-transplant weight gain
Does this trial apply to you?
Post-transplant GLP-1 RA requires the transplant team to be the principal coordinator. Most commercial PA reviewers will approve when the transplant program co-signs the letter. The off-label nature does not preclude approval but does require explicit medical-necessity framing. Tacrolimus levels need monitoring in the first 8 weeks of GLP-1 therapy due to altered GI absorption.
What to ask your prescriber
- Transplant team's position on adding GLP-1 RA
- Current tacrolimus or cyclosporine trough levels and recent trend
- Graft function and rejection risk profile
- Drug-interaction screening for all current immunosuppressants
Editorial notes
- GI side effects from GLP-1 can alter immunosuppressant absorption; monitor levels closely in the first 8 weeks.
- Mycophenolate GI tolerance can be amplified during GLP-1 titration; coordinate the timing of dose escalation.
- This is one of the few clinical situations where deferring GLP-1 therapy until the transplant team explicitly approves is more important than the trial-evidence base.
Clinical trials for Solid organ transplant recipient with obesity
Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.
Take it to your prescriber: PA letter templates
Editable prior-authorization letter templates that cite the registration trial above. Pick the plan your prescriber will submit to, copy the template, fill in the patient-specific findings and have your clinician sign and submit.
Not seeing your plan? The full PA letter librarycovers 20 plans × 10 indications = 200 templates. The appeal letter library handles denials.
Drug profiles
Other GLP-1 conditions
Editorial provenance
Editorial review by John, Editor on 2026-05-23, against No registration RCT in transplant recipients (Observational evidence only as of 2026). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.
Disclaimer
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.